Purpose: This study aimed at developing and validating a novel noninvasive urinary exosome-based post-DRE (digital rectal examination) lncRNA assay to diagnose PCa (prostate cancer) and clinically significant PCa (Gleason score ≥ 7) from the initial prostate biopsy. Methods: A total of 602 urine samples from eligible participants were collected. The expression levels of urinary exosomal PCA3 (prostate cancer antigen 3) and MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) were detected by qPCR (quantitative real-time PCR). Receiver operating characteristic (ROC) analysis was applied to evaluate the diagnostic performance of PCA3, MALAT1 and the lncRNA assay. A decision curve analysis (DCA) and waterfall plots were used to assess the clinical value of the lncRNA assay. Results: Urinary exosomal PCA3 and MALAT1 were overexpressed in PCa and clinically significant PCa (p < 0.001). The lncRNA assay combining PCA3 and MALAT1 had a better diagnostic performance (AUC 0.828) than the current clinical parameters in detecting PCa. More importantly, the lncRNA assay yielded an AUC of 0.831 to detect clinically significant PCa, which is much higher than that of the current clinical parameters. The lncRNA assay was superior to PSA, f/tPSA and the base model for detecting PCa and clinically significant PCa, with a higher net benefit for almost all threshold probabilities. At the cutoff value of 95% sensitivity, the lncRNA assay could avoid 24.2% unnecessary biopsies while only missing 1.2% of the cases of clinically significant PCa. Conclusion: We developed and validated a novel noninvasive post-DRE urine-based lncRNA assay that presented good diagnostic power and clinical utility for the early diagnosis of PCa and high-grade PCa.
Background: The whole-body energy metabolism is regulated by autonomic nerves which also play important roles in the regulation of the generation and development of different kinds of cancers. This study is to analyze the expression of autonomic nerve receptors and their relationship with the development of prostate cancer (PCa) and to further understand the central regulation of the prostate. Methods: RNA sequencing data concerning autonomic nerve receptors from paired tumor and adjacent benign tissues from 65 patients were collected. The mRNA expression and patient data were analyzed. The Cancer Genome Atlas (TCGA) data confirmed the results, and Pearson analysis, Pearson heat maps, gene heat maps, multivariate logistic regression models, receiver operating characteristic (ROC) curves and Gene Set Enrichment Analysis (GSEA) and Pearson’s analysis were analyzed for correlation analysis in this study. Results: Reads with eight receptors associated with PCa generation were finally retained in this report. Favorable relationships were found among the different autonomic nerve regulators for the prostate. In univariate logistic regression analysis, adrenoceptor alpha 1A (ADRA1A) was the most positively correlated [OR (95% CI): 1.707 (1.209, 2.410)]; the area under the curve (AUC) in the ROC for ADRA1A was 0.866 (P<0.001). In multivariate logistic regression analysis, a predicted formulation for PCa diagnosis was evident. The GSEA results also showed the effect of autonomic nerves on cancer generation and some of the key cancer-related pathways, as well as Notch, Wnt and steroid biosynthesis pathways. Finally, five articles were reviewed to elucidate the center-autonomic nerve system-periphery circuit in the prostate. Conclusions: Central regulation plays an important role in the development of PCa, presenting the opportunity to treat the disease, and additional studies are warranted.